Back
Thrombotic Risk of Women with Hereditary Antithrombin III-, Protein C- and Protein S-Deficiency Taking Oral Contraceptive Medication
Journal article

Thrombotic Risk of Women with Hereditary Antithrombin III-, Protein C- and Protein S-Deficiency Taking Oral Contraceptive Medication

  • Pabinger, Ingrid Institute for Medical Statistics, University of Vienna, Austria
  • Schneider, Barbara First Department of Medicine, Division of Hematology and Blood Coagulation and Institute for Medical Statistics, University of Vienna, Austria
  • Scharrer, I Dept. of Angiology, Dept. Med., University Hospital, Frankfurt, Germany
  • Hach-Wunderle, V Dept. of Angiology, Dept. Med., University Hospital, Frankfurt, Germany
  • Lechner, K Dept. of Hematology and Blood Coagulation, First Dept. Med., University Hospital Vienna, Austria
  • Eichinger, S Dept. of Hematology and Blood Coagulation, First Dept. Med., University Hospital Vienna, Austria
  • Kyrle, P A Dept. of Hematology and Blood Coagulation, First Dept. Med., University Hospital Vienna, Austria
  • Vinazzer, H Blood Coagulation Laboratory, Linz, Austria
  • Lämmle, B Central Hematology Laboratory, Inselspital, University Hospital Bern, Switzerland
  • Demarmels-Biasiutti, F Central Hematology Laboratory, Inselspital, University Hospital Bern, Switzerland
  • Tilsner, V Dept. of Surgery, University Hospital Hamburg, Germany
  • Marx, G Dept. of Surgery, University Hospital Hamburg, Germany
  • Scifricd, E Medical University Clinic III, Ulrn, Germany
  • Gabelmann, A Medical University Clinic III, Ulrn, Germany
  • Aspöck, G Central Laboratory, Krankenhaus Weis, Austria
  • Fischer, M Central Laboratory, Krankenhaus der Stadt Wien-Lainz, Vienna, Austria
  • Halbmaycr, W M Central Laboratory, Krankenhaus der Stadt Wien-Lainz, Vienna, Austria
Show more…
  • 2018-7-26
Published in:
  • Thrombosis and Haemostasis. - Georg Thieme Verlag KG. - 1994, vol. 71, no. 05, p. 548-552
Hematology
English SummaryThe thrombotic risk of women with a heterozygous natural clotting inhibitor deficiency taking oral contraceptives (OC) has not been evaluated. Therefore, a retrospective collaborative controlled cohort-study was carried out in 8 coagulation laboratories and thrombosis units in Austria, Germany and Switzerland.The incidence of thromboembolism in 48 females heterozygous for hereditary type I deficiency of antithrombin ITT (n = 1.5), protein C. (n = 16) or protein S (n = 17), who had taken OC at least once in their life were compared with that of 48 deficient women, who had never taken OC (controls). Diagnosis of the deficiency state was made in the participating centers. Data on the onset and duration of OC intake and the date and site of thrombotic events were obtained from a questionnaire filled in by the patient or a physician during a visit at a participating center. The observation period in the OC patients was started with onset of OC intake and was terminated when a thromboembolic event had occurred or when OC medication were discontinued. In the patients without OC, the observation period began at an age matched to that of the OC patient and ended when a thromboembolic event had occurred or was continued as long as the corresponding OC patient was on treatment.In AT Ill-deficient females the probability for thrombosis was significantly higher for patients taking OC compared to the non-OC-patients (Wilcoxon test p = 0.004, Log Rank test p = 0.005). In patients with protein C- ((3-error 0.8) and protein S-deficiency ((3-error 0.05) there was no significant difference between the OC- and non-OC-group. The incidence of thrombosis/patient year in AT III-, PC- and PS-deficient females on OC was 27.5%, 12% and 6.5%, respectively and 3.4%, 6.9% and 8.6%, respectively, in the control patients.We conclude that females with hereditary antithrombin Ill-deficiency are at high risk for venous thromboembolism when taking OC. Therefore, OC should be strictly avoided in these females and AT III measurement is mandatory in female relatives of AT Ill-deficient patients at young age before starting OC. There is no evidence for an excess thrombotic risk by OC intake in PS-deficient females. In protein C-deficient women OC medication was not associated with a significant increase of thrombosis, but an increased risk cannot be excluded.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/14800
Statistics
Document views: 10 File downloads: